Coherus BioSciences (CHRS) Reports Q4 Loss of $1.72/Share

August 9, 2016 4:20 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.72), versus ($1.56) reported last year. Revenue for the quarter came in at $14.07 million, versus $6.87 million reported last year.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment